Cipla Limited

CIPLA

INE059A01026

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 05:13:52 31/05/2024 pm IST			5-day change	1st Jan Change
1,447 ^INR	-1.32%		-2.82%	+16.12%

09:48am	Cipla's Global Chief Technology Officer Retires	MT
30/05	India's pharma export sales to grow faster this year, trade body says	RE

Cipla Limited Announces Resignation of Peter Mugyenyi as Independent Director, Effective May 13, 2023

May 12, 2023 at 07:53 pm IST

Cipla Limited announced the resignation of Peter Mugyenyi as Independent Director of the Company with effect from May 13, 2023.

Latest news about Cipla Limited

Cipla's Global Chief Technology Officer Retires	01:18pm	MT
India's pharma export sales to grow faster this year, trade body says	30/05	RE
Indian drugmakers to see FY25 revenue boost in key US market, says India Ratings and Research	27/05	RE
Nomura Adjusts Cipla’s Price Target to INR1,535 From INR1,486, Keeps at Neutral	23/05	MT
Consumer Goods, Realty Push Indian Equities Higher on Wednesday	22/05	MT
Cipla Arm Gets US FDA Final Nod for Lanreotide Injection	22/05	MT
Cipla Limited Approves the Appointment of Dr. Balram Bhargava as an Independent Director	17/05	CI
Indian Equities Extend Gains on Friday, Led by Real Estate, Auto and Metal Names	17/05	MT
Cipla Invests INR260 Million More in Associate Achira Labs	16/05	MT
Indian Equities Posts Mild Losses on Wednesday Ahead of US Consumer Inflation Data	15/05	MT
INDIA STOCKS-Cipla lifts Indian shares at the open; Canara Bank rises on MSCI inclusion	15/05	RE
Achira Labs Pvt. Ltd. announced that it expects to receive INR 260 million in funding from Cipla Limited	15/05	CI
Cipla Limited Announces Resignation of Jasdeep Singh as Chief Strategy Officer and Senior Management Personnel	14/05	CI
Promoter group to sell stake worth $316 million in India's Cipla, CNBC-TV18 reports	14/05	RE
Indian Equities Close Higher on Tuesday, Led by Auto, Metal Stocks	14/05	MT
Nomura Adjusts Cipla’s Price Target to INR1,486 From INR1,569, Keeps at Neutral	14/05	MT
Indian Equities End Higher on Monday Despite Poll Worries, Foreign Selling	13/05	MT
Jefferies Adjusts Cipla’s Price Target to INR1,400 From INR1,250, Keeps at Hold	13/05	MT
Cipla's Consolidated Net Profit Climbs in Fiscal Q4; Shares Up 6%	13/05	MT
INDIA STOCKS-Election worries, foreign selling spook Indian equities; volatility climbs	13/05	RE
INDIA STOCKS-Indian shares fall as Tata Motors slides; inflation data awaited	13/05	RE
Transcript : Cipla Limited, Q4 2024 Earnings Call, May 10, 2024	10/05
Market Heavyweights Lifts Indian Equities to End Week Higher	10/05	MT
India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says	10/05	RE
India's Cipla beats Q4 profit estimates	10/05	RE

Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products. Net sales by source of income break down between sale of products (96.9%) and services (3.1%). Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).

Sector

Pharmaceuticals

Calendar

03/06/2024 - BofA India Conference

Related indices

NIFTY 50 , NIFTY 100

More about the company

Income Statement Evolution

More financial data

Ratings for Cipla Limited

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,447 INR

Average target price

1,482 INR

Spread / Average Target

+2.42%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
CIPLA LIMITED	+16.12%	14.21B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.91%	42.02B
OTSUKA HOLDINGS CO., LTD.	+22.40%	21.66B
SANDOZ GROUP AG	+18.48%	15.09B
ZYDUS LIFESCIENCES LIMITED	+45.12%	12.37B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-9.58%	6.59B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	5.56B
GEDEON RICHTER	+4.17%	4.64B

Generic Pharmaceuticals

Cipla Limited

Equities

CIPLA

INE059A01026

Pharmaceuticals

Cipla Limited Announces Resignation of Peter Mugyenyi as Independent Director, Effective May 13, 2023

Latest news about Cipla Limited

Chart Cipla Limited

Company Profile

Income Statement Evolution

Ratings for Cipla Limited

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Generic Pharmaceuticals